Literature DB >> 27214393

Intestinal dysbiosis and innate immune responses in axial spondyloarthritis.

Francesco Ciccia1, Angelo Ferrante, Giovanni Triolo.   

Abstract

PURPOSE OF REVIEW: Inflammatory innate and adaptive immune cell responses to commensal bacteria underlie the pathogenesis of human chronic inflammatory diseases. Intestinal dysbiosis has been described in patients with spondyloarthritis (SpA) and seems to be correlated with histologic and immunologic alterations. Purpose of this review is to discuss the relationship occurring between intestinal dysbiosis and innate immune responses in patients with axial SpA. RECENT
FINDINGS: Intestinal dysbiosis and differential activation of intestinal immune responses in patients with SpA have been demonstrated. Furthermore, innate cells that appear to be involved in the pathogenesis of SpA may control intestinal homeostasis through induction of apoptotic cell death and deletion of activated commensal bacteria-specific T cells.
SUMMARY: Although the evidence shows that dysbiosis occurs in SpA, it is not clear the role of dysbiosis in regulating innate immune responses in SpA. Relationships between cause and effect remain to be answered. VIDEO ABSTRACT: http://links.lww.com/COR/A34.

Entities:  

Mesh:

Year:  2016        PMID: 27214393     DOI: 10.1097/BOR.0000000000000296

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  9 in total

Review 1.  Unmet Needs in Axial Spondyloarthritis.

Authors:  Ennio Lubrano; Antonia De Socio; Fabio Massimo Perrotta
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

Review 2.  A Possible Role of Intestinal Microbiota in the Pathogenesis of Ankylosing Spondylitis.

Authors:  Lianjun Yang; Liping Wang; Xin Wang; Cory J Xian; Hai Lu
Journal:  Int J Mol Sci       Date:  2016-12-17       Impact factor: 5.923

3.  Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial.

Authors:  Maja Skov Kragsnaes; Jens Kjeldsen; Hans Christian Horn; Heidi Lausten Munk; Finn Moeller Pedersen; Hanne Marie Holt; Jens Kristian Pedersen; Dorte Kinggaard Holm; Henning Glerup; Vibeke Andersen; Ulrich Fredberg; Karsten Kristiansen; Robin Christensen; Torkell Ellingsen
Journal:  BMJ Open       Date:  2018-04-27       Impact factor: 2.692

Review 4.  The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science.

Authors:  Abdulla Watad; Charlie Bridgewood; Tobias Russell; Helena Marzo-Ortega; Richard Cuthbert; Dennis McGonagle
Journal:  Front Immunol       Date:  2018-11-16       Impact factor: 7.561

Review 5.  The Molecular Pathophysiology of Psoriatic Arthritis-The Complex Interplay Between Genetic Predisposition, Epigenetics Factors, and the Microbiome.

Authors:  Ana L Carvalho; Christian M Hedrich
Journal:  Front Mol Biosci       Date:  2021-04-01

6.  Expanded IL-22+ Group 3 Innate Lymphoid Cells and Role of Oxidized LDL-C in the Pathogenesis of Axial Spondyloarthritis with Dyslipidaemia.

Authors:  Hong Ki Min; Jeonghyeon Moon; Seon-Yeong Lee; A Ram Lee; Chae Rim Lee; Jennifer Lee; Seung-Ki Kwok; Mi-La Cho; Sung-Hwan Park
Journal:  Immune Netw       Date:  2021-11-18       Impact factor: 6.303

Review 7.  Intestinal Barrier in Human Health and Disease.

Authors:  Natalia Di Tommaso; Antonio Gasbarrini; Francesca Romana Ponziani
Journal:  Int J Environ Res Public Health       Date:  2021-12-06       Impact factor: 3.390

Review 8.  Practical Significance of Biomarkers in Axial Spondyloarthritis: Updates on Diagnosis, Disease Activity, and Prognosis.

Authors:  Alexandra-Diana Diaconu; Alexandr Ceasovschih; Victorița Șorodoc; Cristina Pomîrleanu; Cătălina Lionte; Laurențiu Șorodoc; Codrina Ancuța
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

9.  Crossing the boundaries: IL-23 and its role in linking inflammation of the skin, gut and joints.

Authors:  Zuzanna Łukasik; Eric Gracey; Koen Venken; Christopher Ritchlin; Dirk Elewaut
Journal:  Rheumatology (Oxford)       Date:  2021-10-19       Impact factor: 7.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.